DVI AtheroCath-GTO U.S. sales to resume following approval of PMA supplement.
This article was originally published in The Gray Sheet
DVI ATHEROCATH-GTO U.S. MARKETING WILL RESUME FOLLOWING FDA APPROVAL of a premarket approval application supplement covering modifications made to the device, the company said. Until FDA approves the recently filed supplement, Devices for Vascular Intervention will be selling an earlier generation atherectomy device, the AtheroCath SCA-EX. The SCA-EX has continued to be available since the full market release of the GTO in September 1994.
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.